STOCK TITAN

SpyGlass Pharma: Vensana Capital I distributes 331K shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

SpyGlass Pharma, Inc. (SGP) reported share movements involving Vensana Capital I, L.P. and Vensana Capital I GP, LLC in a Form 4 filed by director Kirk G. Nielsen. On November 16, 2026, Vensana Capital I distributed 331,036 shares pro rata to its partners without additional consideration. Vensana Capital I GP received 8,646 shares in an in-kind distribution and distributed 8,634 shares pro rata to its members without consideration. The footnotes describe the distributions as not purchases or sales and say Kirk G. Nielsen disclaims beneficial ownership, except to the extent of his pecuniary interest.

Insider Nielsen Kirk G.
Role Director
Type Security Shares Price Value
Other Common Stock F1, F2 331,036 $0.00 $0.00
Other Common Stock F3, F4 8,646 $0.00 $0.00
Other Common Stock F5, F4 8,634 $0.00 $0.00
Holdings After Transaction: Common Stock — 12 shares (Indirect, See Footnote)
Footnotes (5)
  1. F1. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Vensana Capital I, L.P. ("Vensana I") to its partners.
  2. F2. These shares are held directly by Vensana I. Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
  3. F3. Represents a change in the form of ownership of Vensana GP I by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Vensana I.
  4. F4. Shares are held by Vensana GP I. Each of the GP I Managing Directors is a managing director of Vensana GP I. Each of the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana GP I. Each of the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
  5. F5. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Vensana GP I to its members.
Shares distributed 331,036 shares Vensana Capital I to its partners on November 16, 2026
Shares received 8,646 shares Vensana Capital I GP in an in-kind distribution on November 16, 2026
Shares distributed 8,634 shares Vensana Capital I GP to its members on November 16, 2026
pro-rata distribution financial
"pro-rata distribution to its partners"
A pro-rata distribution is when cash, shares, rights or other assets are divided among investors in proportion to their ownership stake, so each holder gets the same percentage of the total as their share of the company. Think of slicing a pie so everyone receives pieces sized to match how much of the pie they own. For investors this matters because it preserves relative ownership and determines how much value or new securities they receive, and whether they need to buy or sell to maintain their position.
in-kind distribution financial
"receipt of shares in the pro-rata in-kind distribution"
A distribution of value to shareholders or beneficiaries made by transferring assets instead of paying cash, such as shares, bonds, or property. Like receiving a box of goods rather than money, it changes what you hold rather than adding liquid funds; investors care because it affects a portfolio’s composition, liquidity, tax reporting, and cost basis for the received assets.
beneficial ownership regulatory
"disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What SGP share movements involving director Kirk G. Nielsen were reported?

The report records three entity-level movements on November 16, 2026: Vensana Capital I distributed 331,036 shares to partners; Vensana Capital I GP received 8,646 shares in an in-kind distribution and distributed 8,634 shares to members.

Were the SGP share movements purchases or sales?

The 331,036-share and 8,634-share transactions are described as pro-rata distributions, not purchases or sales; the 8,646 shares were received in an in-kind distribution for no consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nielsen Kirk G.

(Last)(First)(Middle)
C/O SPYGLASS PHARMA, INC. 15326
ALTON PARKWAY

(Street)
IRVINE CALIFORNIA 92618

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026J(1)331,036D$0.002,979,583ISee footnote(2)
Common Stock11/16/2026J(3)8,646A$0.008,646ISee Footnote(4)
Common Stock11/16/2026J(5)8,634D$0.0012ISee Footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Vensana Capital I, L.P. ("Vensana I") to its partners.
2. These shares are held directly by Vensana I. Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
3. Represents a change in the form of ownership of Vensana GP I by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Vensana I.
4. Shares are held by Vensana GP I. Each of the GP I Managing Directors is a managing director of Vensana GP I. Each of the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana GP I. Each of the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
5. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Vensana GP I to its members.
/s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading